Application of CLGAB pretreatment regimen in autologous hematopoietic stem cell transplantation for refractory recurrent lymphoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042685

Enrollment

Unknown

Registered

2021-01-26

Start date

2021-02-01

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma

Interventions

experimental group:Clad+GEM+Ara-C+BU

control group:BCNU+VP16+Ara-C+Mel

Eligibility

Sex/Gender

All

Age

14 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. With complete data, confirmed by clinicopathology, and immunohistochemical reports of high-risk and refractory lymphoma, including: double-expressed or double-hit lymphoma (refractory), or young and highly aggressive lymphoma or lymphoma with early recurrence; 2. Patients who do not agree or have no conditions for allogeneic hematopoietic stem cell transplantation; 3. Age over 14 years old, less than 60 years old, male or female.

Exclusion criteria

Exclusion criteria: 1. Patients with severe underlying diseases; 2. ECOG score of physical status >= 3; 3. Qualified for allogeneic hematopoietic stem cell transplantation.

Design outcomes

Primary

Measure	Time frame
overall survival;Progression-free survival;Cumulative recurrence rate;	—

Secondary

Measure	Time frame
Transplant-related short-term outcomes;adverse reaction;Transplant-related mortality;	—

Countries

China

Contacts

Public ContactChen Xiangli

People's Hospital of Henan Province

snowdrop999@163.com+86 13592634578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026